

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): July 13, 2020

DLH Holdings Corp.

(Exact Name of Registrant as Specified in Charter)

New Jersey
(State or Other Jurisdiction
of Incorporation)

0-18492
(Commission
File Number)

22-1899798
(I.R.S. Employer
Identification No.)

3565 Piedmont Road, NE
Building 3, Suite 700
Atlanta, GA 30305
(Address of Principal Executive Offices, and Zip Code)

(866) 952-1647
Registrant's Telephone Number, Including Area Code
Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	DLHC	Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 13, 2020, DLH Holdings Corp. (the “Company”) terminated Kevin H. Beverly’s employment as the Operating Unit President of the Company’s Social & Scientific Systems, Inc. subsidiary. To support an efficient transition, Mr. Beverly has agreed to remain in the employ of the Company in an advisory capacity through July 30, 2020 to provide transition support advice. In connection with such arrangements, upon the termination of Mr. Beverly’s employment in such advisory capacity, he will be entitled to receive accrued compensation, severance payments, and continuation coverage in accordance with that certain Change in Control, Severance and Covenant Agreement effective as of October 18, 2019, and a pro-rated incentive bonus for fiscal year 2020 equal to 50% of his current base salary, subject to his execution and non-revocation of a separation and release of claims agreement. In addition, effective upon the final date of his employment, the Company will accelerate the vesting of 50,000 unvested options granted to Mr. Beverly as of October 18, 2019, that otherwise would have vested on the one-year anniversary of the grant date.

Item 8.01. Other Events.

On July 13, 2020, the Company published a press release announcing changes to its leadership team. In its press release, the Company announced that, effective July 13, 2020, it has named Jacqueline S. Everett as its Chief Growth Officer and Jeanine M. Christian as the Operating Unit President of its Social & Scientific Systems, Inc. subsidiary. As Chief Growth Officer, Ms. Everett will be responsible for the Company’s enterprise-wide business development activities and will report to Zachary C. Parker, the President and Chief Executive Officer of the Company. Ms. Christian, as President of the Company’s Social & Scientific Systems subsidiary, will be responsible for leading the Company’s Public Health and Life Sciences operations and will also report to Mr. Parker. A copy of the press release announcing the changes reported in this Current Report on Form 8-K is attached hereto as Exhibit 99.1 and is hereby incorporated into this Item 8.01 by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is being filed as part of this Current Report on Form 8-K:

<u>Exhibit Number</u>	<u>Exhibit Title or Description</u>
99.1	Press Release dated July 13, 2020

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

DLH Holdings Corp.

By: /s/ Kathryn M. JohnBull

Name: Kathryn M. JohnBull

Title: Chief Financial Officer

Date: July 17, 2020

DLH Announces Executive Appointments

Atlanta, Georgia – July 13, 2020 – DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading healthcare and human services provider to the federal government, today announced executive leadership appointments effective July 13, 2020. Jeanine Christian joins DLH as President, Social & Scientific Systems (“S3”), and Jacqueline Everett is appointed as DLH Chief Growth Officer.

In her role as President of the Company’s S3 operating unit, Ms. Christian succeeds Kevin Beverly and will lead operations focused on the Public Health and Life Sciences market. Having spent over 20 years in science-based organizations, she most recently led a team of over 300 scientists, clinicians, researchers, and data analysts whose mission it was to translate scientific discovery and technology advances into societal benefits for federal and state government, non-profit, academic, and commercial clients. Ms. Christian’s last role was Vice President & Business Line Manager of the Public Health Research Division with Battelle Memorial Institute. Prior to that, she directed various impactful research programs as a Senior Study Director at Westat. As S3 President, her responsibilities will include strategic direction of the operating unit, customer relationship management, program execution, human resources, and generating business growth.

Ms. Everett joins DLH as Chief Growth Officer. In this role, she will spearhead enterprise-wide business development activities, establishing the vision, direction, and strategy required to achieve the Company’s growth objectives. She brings over 25 years of successful experience in the government contracting industry, most recently as Vice President Business Development & Strategy with Leidos. Prior to that, she held business development leadership positions with DXC Technology, CSC and Serco.

“I am proud to announce these changes to our leadership structure, which we are confident will enable DLH to further capitalize on our highly-talented workforce, broad capabilities, and longstanding demand for the services we provide,” said DLH President and CEO Zach Parker. “Jeanine’s scientific expertise, customer relationships, effective leadership, and results-oriented approach to business make her a fantastic fit for DLH. At the same time, Jackie Everett is recognized throughout our industry as an accomplished, dynamic leader. Her drive, motivation, and experience are expected to enable DLH to execute our strategic vision. I am pleased that both are joining us at this critical time in our growth trajectory.

“I also want to thank Kevin Beverly for his leadership and for being an invaluable partner throughout the acquisition and integration of S3 into DLH. With Kevin at the helm, S3 grew to be a leading public health service organization providing solutions in clinical and biomedical research, epidemiology, health policy, and program evaluation. He will remain on board in an advisory role to support us in this transition; we are grateful for his many contributions and wish him all the best as he writes his next chapter.”

About DLH

DLH (NASDAQ:DLHC) serves federal government clients throughout the United States and abroad delivering technology enabled solutions in key health and human services programs. The Company’s seven core competencies include secure data analytics, clinical trials and laboratory services, case management, performance evaluation, system modernization, operational logistics and readiness, and strategic digital communications. DLH has over 1,950 employees serving numerous government agencies. For more information, visit the corporate website at www.dlhcorp.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2019, and subsequent filings we make with the SEC from time to time. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date

hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.

INVESTOR RELATIONS

Contact: Chris Witty

Phone: 646-438-9385

Email: cwitty@darrowir.com

<https://dlhcorp.investorroom.com/2020-07-13-DLH-Announces-Executive-Appointments>
